Apart from vorinostat and romidepsin, other HDAC inhibitors such as belinostat and panobinostat have been investigated in clinical trials for CTCL and other hematological malignancies, showing varying degrees of efficacy [18]. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.